Evidence map›Paper›PMID 39322925›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Caveolin-1 modulates cisplatin sensitivity in oral squamous cell carcinoma through ferroptosis.

Weilin Zhang, Xinyi Yang, Wei Lin, Yang Yi, Hai Wu, Jiangying Yang, Hongman Long, Guanglan Zou, Yadong Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weilin ZhangSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.ORCID http://orcid.org/0009-0002-3691-9484
Xinyi YangSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Wei LinSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Yang YiSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Hai WuSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Jiangying YangSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Hongman LongSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China.
Guanglan ZouDepartment of Pathology, Stomatological Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Yadong WuSchool of Stomatology, Guizhou Medical University, Guiyang, Guizhou, China. woooyadong@163.com.

Funding

the Horizontal Project of the School of Stomatology, Guizhou Medical University GYKQ2022HXZD02the National Natural Science Foundation of China 82060498
6 · The paper itself

Abstract

objectiveCisplatin-based chemotherapy is widely used for the treatment of oral squamous cell carcinoma (OSCC), but drug resistance and decreased sensitivity often occur during the treatment, greatly weakening its therapeutic effect. Caveolin-1 (CAV1), a protein related to ferroptosis, is involved in regulating the resistance and sensitivity of various tumor chemotherapies. This study aims to investigate whether CAV1 can regulate the sensitivity of OSCC to cisplatin through ferroptosis.

methodsThrough bioinformatics analysis, we analyzed the expression of CAV1 in OSCC and its impact on prognosis analyzed the relationship between CAV1 and tumor immune infiltration, and verified the expression of CAV1 in OSCC through immunohistochemistry experiments. We silenced the expression of CAV1 in OSCC cells through lentiviral transfection and evaluated the cell migration and invasion abilities through wound healing and Transwell assays, respectively. CCK8 assay was used to assess the sensitivity of cells to cisplatin, and ferroptosis-related biochemical marker changes were measured. Western blot was performed to detect the expression of ferroptosis-related proteins.

resultsThe results revealed a high expression of CAV1 in OSCC, and its high expression predicted poor prognosis in OSCC. CAV1 is associated with drug metabolism pathways in OSCC, and its expression affects the infiltration levels of various immune cells in tumors. Further experiments indicated that CAV1 can inhibit ferroptosis and cisplatin sensitivity in cancer cells, promoting their migration and invasion.

conclusionCAV1 promotes the progression of OSCC and can affect the sensitivity of cisplatin by regulating cellular ferroptosis.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellCaveolin 1CisplatinDrug Resistance, NeoplasmFerroptosisMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckCell Line, TumorCell MovementFemaleHumansMaleMiddle AgedPrognosisAntineoplastic AgentsCAV1 protein, humanCaveolin 1CisplatinCAV1ChemotherapyFerroptosisOral squamous carcinoma cells

Identifiers

PMID39322925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.